EndoTODAY | EndoATLAS | Outpatient Clinic
Parasite | Esophagus | Stomach | Cancer | ESD
Home | Guide | Author | Subscription | Links
[Thursday Endoscopy Conference 20160804]
1. EGC (initially negative biopsy after referral for biopsy-proven gastric cancer)
ÀÇ·Ú ÈÄ Ã¹ °Ë»ç¿¡¼ ¾ÏÀÌ È®ÀεÇÁö ¾Ê¾ÒÀ¸³ª Àç°Ë¿¡¼ È®ÀεǾú°í Ä¡·á ÈÄ ÃÖÁ¾ÀûÀ¸·Î´Â 2.1 cm Á¡¸·¾ÏÀ̾ú½À´Ï´Ù.
ÀÌó·³ ¿ÜºÎ¿¡¼ ¾ÏÀÌ ³ª¿Í ÀǷڵǾú´Âµ¥ Àç°Ë¿¡¼ ¾ÏÀÌ ³ª¿ÀÁö ¾ÊÀ¸¸é ȯÀÚ³ª ÀÇ»ç ¸ðµÎ ³°¨ÇØÁý´Ï´Ù. Ä¡·á¹æħÀ» Á¤Çϱ⠾î·Æ±â ¶§¹®ÀÔ´Ï´Ù. ÀÛ°í ÇÔ¸ôÇüÀÌ ¾Æ´Ï°í °æ°è°¡ ¸íÈ®ÇÏ´Ù¸é Áø´Ü ¹× Ä¡·á¸¦ À§ÇÑ ESD¸¦ ½ÃÇàÇÒ ¼öµµ ÀÖ½À´Ï´Ù. ±×·¸Áö ¾Ê´Ù¸é Áï½Ã Àç°ËÀ» ÇÏ°í, ±×·¡µµ ¾È ³ª¿À¸é short-term ÃßÀû°üÂûÀ» ÇØ¾ß ÇÕ´Ï´Ù.
Á¦°¡ ³»½Ã°æÀ» ¹è¿ï ¶§¿¡´Â Çѹø ¾ÏÀÌ ³ª¿À°í Àç°Ë¿¡¼ ¾ÏÀÌ ³ª¿ÀÁö ¾ÊÀº °æ¿ì ¼ö¼úÀ» ÇÏ´Â ¿¹°¡ ¸¹¾Ò½À´Ï´Ù. ±×·±µ¥ ¿äÁòÀº Àç°ËÀ» ÅëÇÏ¿© È®ÀÎÇÑ ÈÄ Ä¡·á¹æ¹ýÀ» ´Ù½Ã °í¹ÎÇÏ´Â °ÍÀÌ º¸ÅëÀÔ´Ï´Ù.
°ü·ÃµÈ ¹®ÇåÀº °ÅÀÇ ¾ø½À´Ï´Ù. ¾Æ¸¶ ÀúÈñ ÆÀ¿¡¼ ¹ßÇ¥ÇÑ ÀÚ·á(Tae CH. Gut Liver 2016)°¡ À¯ÀÏÇÑ referenceÀÏ °ÍÀÔ´Ï´Ù. 2015³â 5¿ù 14ÀÏ EndoTODAY¿¡ ¼Ò°³ÇÑ ¹Ù ÀÖÀ¸³ª ´Ù½Ã Çѹø ¿Å±é´Ï´Ù. ±×¸®°í ÀÌ¾î¼ ½ÇÁ¦·Î Á¦°¡ ¿Ü·¡¿¡¼ ¾î¶»°Ô ¼³¸íÇÏ°í ÀÖ´ÂÁö ¸»¾¸µå¸®„E½À´Ï´Ù.
Ÿ º´¿ø ³»½Ã°æ Á¶Á÷°Ë»ç¿¡¼ À§¾ÏÀ¸·Î Áø´ÜµÇ¾î ÀÇ·ÚµÈ È¯ÀÚÀÇ ³»½Ã°æ Àç°Ë¿¡¼ ¾ÏÀÌ ³ª¿ÀÁö ¾Ê¾Æ ´çȤ½º·¯¿ü´ø °æÇèÀº ¾øÀ¸½Ê´Ï±î? ¸¹Àº ºÐµéÀÌ ±×·± °æÇèÀ» °¡Áö°í °è½Ç °ÍÀÔ´Ï´Ù. °¨Ãß°í ½ÍÀº ¾²¸° °æÇèÀ̾ú°ÚÁö¸¸.
±×·± »ç·ÊµéÀ» ¸ð¾Æ ³í¹®À¸·Î ²Ù¸ì½À´Ï´Ù. ¸î¸î Àú³Î¿¡ Åõ°íÇßÀ¸³ª ´ëºÎºÐ reject µÇ¾ú½À´Ï´Ù. ±Ý¹æ reject µÇ¾ú½À´Ï´Ù. "³ÊÈñ°¡ °Ë»ç¸¦ ¸øÇؼ ±×·± °ÍÀÌ´Ù" ÅõÀÇ comment°¡ ¾²ÀÎ reject letter¸¦ ¹ÞÀ¸´Ï ¹¦ÇÑ ±âºÐÀÌ´õ±º¿ä. Thomas KuhnÀÌ '°úÇÐÇõ¸íÀÇ ±¸Á¶(The Structure of Scientific Revolutions)'¿¡¼ ¼³¸íÇÑ ¹Ù·Î ±× Æó¼â¼ºÀ» ´À²¼½À´Ï´Ù. Normal science¿¡¼ ¹þ¾î³ °á°ú´Â ÀÏ´Ü ¹«½ÃÇÏ´Â °ÍÀÌ ÇаèÀÇ ±âº» ¼ºÇâÀÎ ¸ð¾çÀÔ´Ï´Ù.
¹°·Ð ÀÎÁ¤ÇÕ´Ï´Ù. À§¾ÏÀÇ Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀÌ È®ÀεǸé Á¤»óÀÌ°í, ¾ÏÀÌ È®ÀεÇÁö ¾ÊÀ¸¸é ºñÁ¤»óÀÔ´Ï´Ù. ±×·±µ¥ ´Ã ±×·± °Íµµ ¾Æ´Õ´Ï´Ù. ¿ì¸® ¸ðµÎ °æÇèÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. Fellow ½ÃÀý¿¡ ±³¼ö´ÔÀÇ À§¾Ï ȯÀÚ¸¦ °Ë»çÇÏ¿© Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀÌ ³ª¿ÀÁö ¾ÊÀ¸¸é ¹«Ã´ °ï¶õÇÑ ÀÏÀÌ ¹ú¾îÁý´Ï´Ù. ¾Æ¸¶ ºÒ·Á°¡¼ È¥³ ºÐµµ °è½Ç °ÍÀÔ´Ï´Ù. ºÒÆíÇÑ Àüȸ¦ ¹ÞÀº ºÐµµ °è½Ç °ÍÀÔ´Ï´Ù. ±×·± °æÇèÀº ¸ðµÎ ºñÁ¤»óÀϱî¿ä? Àú¸¸ À¯³È÷ ¸ø³ °ÍÀϱî¿ä? ±³¼ö°¡ Á÷Á¢ °Ë»çÇϸé Ç×»ó ¾ÏÀÌ ³ª¿Ã±î¿ä? °¨Ãß°í ½ÍÀº ºÒÆíÇÑ Áø½ÇÀº ¹«¾ùÀϱî¿ä?
¸¶Ä§³» ÇÑ Àú³Î¿¡¼ ÀúÈñ ÀڷḦ accept ÇØ ÁÖ¾ú½À´Ï´Ù. °í¸¶¿î ÀÏÀÌ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. °¨»çÇÕ´Ï´Ù. ¿©·¯ºÐÀÇ ¿¹»óó·³ Á¦¸ñ ¶ÇÇÑ Á¶±Ý ÀÌ»óÇÕ´Ï´Ù. Negative biopsy after referral for biopsy-proven gastric cancer (Gut Liver 2016)
BACKGROUND/AIMS: Repeat endoscopy with biopsy is often performed in patients with previously diagnosed gastric cancer to determine further treatment plans. However, biopsy results may differ from the original pathologic report. We reviewed patients who had a negative biopsy after referral for gastric cancer.
METHODS: A total of 116 patients with negative biopsy results after referral for biopsy-proven gastric cancer were enrolled. Outside pathology slides were reviewed. Images of the first and second endoscopic examinations were reviewed. We reviewed the clinical history from referral to the final treatment.
RESULTS: Eighty-eight patients (76%) arrived with information about the lesion from the referring physician. Among 96 patients with available outside slides, the rate of interobserver variation was 24%. Endoscopy was repeated at our institution; 85 patients (73%) were found to have definite lesions, whereas 31 patients (27%) had indeterminate lesions. In the group with definite lesions, 71% of the lesions were depressed in shape. The most common cause of a negative biopsy was mistargeting. In the group with indeterminate lesions, 94% had insufficient information. All patients with adequate follow-up were successfully treated based on the findings in the follow-up endoscopy.
CONCLUSIONS: A negative biopsy after referral for biopsy-proven gastric cancer is mainly caused by mistargeting and insufficient information during the referral.
ÀÚ¼¼ÇÑ ³»¿ëÀº ³í¹®À» Àо½Ã±â ¹Ù¶ø´Ï´Ù. Á¦°¡ °Á¶ÇÏ°í ½ÍÀº °ÍÀº ÀÌ°ÍÀÔ´Ï´Ù. "¸î ¹ø °Ë»çÇÏ´Ùº¸¸é ´ëºÎºÐ ¾ðÁ¨°¡´Â ¾ÏÀ¸·Î ³ª¿ÀÁö¸¸ ÀüºÎ°¡ ´Ù ¾ÏÀ¸·Î ³ª¿À´Â °ÍÀº ¾Æ´Ï´Ù."
³ª»Û °á°ú´Â µü ÇѸíÀ̾ú½À´Ï´Ù. ÀÇ»çÀÇ ±ÇÀ¯¸¦ µû¸£Áö ¾Ê¾Ò´ø ºÐÀÔ´Ï´Ù. ÃßÀû ³»½Ã°æÀ» ¹ÞÁö ¾Ê°í Áö³»´Ù°¡ 5³â ¸¸¿¡ º¸¸¸ 4Çü ÁøÇ༺ À§¾ÏÀ¸·Î Áø´ÜµÇ¾ú½À´Ï´Ù. .
ÀÓ»ó°»ç, Àü°øÀÇ ¿©·¯ºÐ. Ȥ½Ã ±³¼ö´Ô ȯÀÚÀÇ Á¶Á÷°Ë»ç¿¡¼ À§¾ÏÀÌ ³ª¿ÀÁö ¾Ê´õ¶óµµ ³Ê¹« ½Ç¸ÁÇÏÁö ¸¶½Ê½Ã¿À. ³²µéµµ ±×·± °æÇèÀ» ¸¹ÀÌ °¡Áö°í ÀÖ½À´Ï´Ù. ´Ù¸¸ °¨Ãß°í ÀÖÀ» »ÓÀÔ´Ï´Ù. 'ȯÀÚ-ÀÇ»ç °ü°è'°¡ ÁÁÀ¸¸é ¸ðµÎ ÁÁÀº °á°ú°¡ ³ª¿É´Ï´Ù. ÀûÀýÇÑ ÃßÀû°üÂûÀÌ Áß¿äÇÏ´Ù°í »ý°¢ÇÕ´Ï´Ù.
Çö½ÇÀûÀ¸·Î Àú´Â ¾Æ·¡¿Í °°ÀÌ ¼³¸íÇÏ°í ÀÖ½À´Ï´Ù (Âü°í: ÀÌÁØÇà ¿Ü·¡ ¼³¸í¼)
[ÀÇ·Ú ÈÄ Ã¹ Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀÌ È®ÀεÇÁö ¾ÊÀº °æ¿ì]
º´ÀÌ ÀÛÀ¸¸é ȯÀÚ¿¡°Ô´Â ÁÁÀº ÀÏÀÌÁö¸¸ ÀÇ·áÁø¿¡°Ô´Â ±î´Ù·Î¿î ¸éÀÌ ÀÖ½À´Ï´Ù. Áø´Ü°ú Ä¡·á°á°ú Çؼ®ÀÌ ½±Áö ¾Ê±â ¶§¹®ÀÔ´Ï´Ù. º´ÀÌ Å©¸é Áø´Ü°ú Ä¡·á ¿øÄ¢ÀÌ ¸íÈ®ÇØÁöÁö¸¸ ȯÀÚ¿¡°Ô´Â ³ª»Û ÀÏÀÔ´Ï´Ù. ÀÛÀº À§¾ÏÀº ¹ß°ßÇϱ⠾î·Æ½À´Ï´Ù. Á¶Á÷°Ë»ç ÈÄ¿¡´Â ¸ð¾çÀÌ ´Þ¶óÁö¹Ç·Î ´õ¿í ¾î·Æ½À´Ï´Ù. ù Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀ¸·Î È®ÀεǾúÀ¸³ª Àç°Ë¿¡¼ È®ÀεÇÁö ¾Ê¾ÒÀ» ¶§¿¡´Â ÀÏ´Ü Àç°ËÇغ¸´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. ±×·¡µµ È®ÀεÇÁö ¾ÊÀ¸¸é »ó´çÇÑ °í¹ÎÀÌ ÇÊ¿äÇÕ´Ï´Ù.
[µÎ¹ø°¿¡¼µµ ¾È ³ª¿ÔÀ» ¶§]
º´ÀÌ ÀÛÀ¸¸é ȯÀÚ¿¡°Ô´Â ÁÁÀº ÀÏÀÌÁö¸¸ ÀÇ·áÁø¿¡°Ô´Â ±î´Ù·Î¿î ¸éÀÌ ÀÖ½À´Ï´Ù. Áø´Ü°ú Ä¡·á°á°ú Çؼ®ÀÌ ½±Áö ¾Ê±â ¶§¹®ÀÔ´Ï´Ù. º´ÀÌ Å©¸é Áø´Ü°ú Ä¡·á ¿øÄ¢ÀÌ ¸íÈ®ÇØÁöÁö¸¸ ȯÀÚ¿¡°Ô´Â ³ª»Û ÀÏÀÔ´Ï´Ù. ÀÛÀº À§¾ÏÀº ¹ß°ßÇϱ⠾î·Æ½À´Ï´Ù. Á¶Á÷°Ë»ç ÈÄ¿¡´Â ¸ð¾çÀÌ ´Þ¶óÁö¹Ç·Î ´õ¿í ¾î·Æ½À´Ï´Ù. ù Á¶Á÷°Ë»ç¿¡¼ ¾ÏÀ¸·Î È®ÀεǾúÀ¸³ª ¹Ýº¹µÈ Àç°Ë¿¡¼ È®ÀεÇÁö ¾Ê¾ÒÀ» ¶§ ¾î¶»°Ô ÇÏ´Â °ÍÀÌ ÃÖ¼±ÀÏÁö Àü¹®°¡µé »çÀÌ¿¡¼µµ ÀÇ°ßÀÌ ºÐºÐÇÕ´Ï´Ù.
¿©·¯ Àǻ翡°Ô ¹°¾îº¸¸é ¸ðµÎ ´Ù¸¥ ÀÇ°ßÀ» °¡Áö°í ÀÖ½À´Ï´Ù. º´ÀÌ ³Ê¹« À۾Ƽ ¹ß»ýÇÏ´Â ¹®Á¦ÀÎ °æ¿ì°¡ ¸¹Áö¸¸, ±Ë¾çÇü À§¾ÏÀÇ °æ¿ì ¼¼Æ÷°¡ Å»¶ôµÇ¾î ÀÌ·¯ÇÑ ÀÏÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. µå¹°°Ô º´ÀÌ Á¡¸·ÇÏ·Î ÀÚ¶ó´Â ŸÀÔÀ̱⠶§¹®¿¡ Á¶Á÷°Ë»ç¿¡¼ ¾È ³ª¿À´Â ¼öµµ ÀÖ½À´Ï´Ù. ȯÀÚºÐÀÇ ´ä´äÇÑ ¸¶À½Àº Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù¸¸, ±â°è°¡ ¾Æ´Ñ Àΰ£ÀÇ ¸öÀ» ´ë»óÀ¸·Î ÇÏ´Â ÀÇÇп¡´Â ÀÌ·± ºÎºÐÀÌ ¸¹½À´Ï´Ù. µÎ °¡Áö ¹æ¹ýÀÌ ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù.
(1) ¿ì¼± ¿ÜºÎ °á°ú¸¦ ¹Ï°í Áö±Ý ´çÀå ¼ö¼úÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ýÀº ¾ÏÀÇ Ä¡·á°¡ Áö¿¬µÇÁö ¾Ê´Â´Ù´Â °ÍÀÌ ÀåÁ¡ÀÔ´Ï´Ù. ±×·¯³ª ±¤¹üÀ§ÇÑ À§ÀýÁ¦¼ú ÈÄÀÇ º´¸®Á¶Á÷¿¡¼ ¾ÏÀÌ È®ÀεÇÁö ¾Ê´Â ¼ö°¡ ÀÖ½À´Ï´Ù. À̴ ù º´¼ÒÀÇ Å©±â°¡ ¸Å¿ì À۱⠶§¹®¿¡ ¹ß»ýÇÏ´Â ¹®Á¦ÀÏ °ÍÀÔ´Ï´Ù. ¸Å¿ì ÀÛÀº À§¾ÏÀº Á¶Á÷°Ë»ç¸¸À¸·Îµµ Á¦°ÅµÉ ¼ö ÀÖÀ» °ÍÀ̸ç, Á¶Á÷°Ë»ç·Î Á¦°ÅµÇÁö ¾Ê¾Ò´Ù°í ÇÏ´õ¶ó°í ¼ö¼ú ÈÄ º´¸®°Ë»çÀÇ ½½¶óÀÌµå »ùÇÿ¡ À§¾ÏÁ¶Á÷ÀÌ Æ÷ÇÔµÇÁö ¾ÊÀ» ¼öµµ ÀÖ½À´Ï´Ù. ¼ö¼ú±îÁö Çߴµ¥ ¾ÏÀÌ È®ÀεÇÁö ¾Ê´Â´Ù¸é ȯÀÚ ÀÔÀå¿¡¼´Â ´õ¿í È¥¶õ½º·¯¿ï °ÍÀÔ´Ï´Ù (³»°¡ ¾ÏÀ̶ó´Â ¸»Àΰ¡ ¾Æ´Ï¶ó´Â ¸»Àΰ¡???). ¾ÆÁÖ °£È¤ Á¶Á÷°Ë»ç »ùÇÃÀÌ ¹Ù²î¾î ¾ÏÀÌ ¾Æ´Ñµ¥ ¾ÏÀ¸·Î ³ª¿À´Â °æ¿ìµµ ÀÖÀ» °ÍÀÔ´Ï´Ù (ÀÇ·á°¡ Àü»êÈµÈ ÃÖ±Ù¿¡´Â µå¹® ÀÏÀÔ´Ï´Ù).
(2) ´Ù¸¥ ¹æ¹ýÀº ÃßÀû ³»½Ã°æ °Ë»ç¸¦ ÇÏ¸é¼ ´Ù½Ã ¾ÏÀÌ ³ª¿À¸é ±× ¶§ Ä¡·áÇÏ´Â Àü·«ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù¹ýÀº ¼ö¼ú Àü º´¼Ò¿¡ ´ëÇÑ Æò°¡°¡ ¸íÈ®ÇÏ´Ù´Â ÀåÁ¡ÀÌ ÀÖÀ¸³ª ¾ÏÀÇ Ä¡·á°¡ Áö¿¬µÉ ¼ö ÀÖ´Ù´Â ´ÜÁ¡µµ ÀÖ½À´Ï´Ù. ¸î ³â ÈÄ À§¾ÏÀÌ ÁøÇ༺À¸·Î ³ª¿À¸é, º¸´Ù ÀÏÂï Ä¡·áÇÏÁö ¾Ê¾Ò´ø °ÍÀ» ȯÀÚµéÀÌ ÈÄȸÇÒ ¼ö ÀÖ´Â ÀÏÀÔ´Ï´Ù.
Çö½ÇÀûÀ¸·Î´Â ´Ù½Ã Çѹø ³»½Ã°æÀ» ÇØ º¸´Â °ÍÀÌ ÃÖ¼±ÀÔ´Ï´Ù. ¸¸¾à¿¡ Àç°Ë¿¡¼µµ ¾ÏÀÌ ³ª¿ÀÁö ¾ÊÀ¸¸é ¾Õ¼ ¾ð±ÞÇÑ µÎ ¹æ¹ý Áß Çϳª¸¦ ¼±ÅÃÇÒ ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù.
[2016-8-5. ¾Öµ¶ÀÚ ÆíÁö]
¿À´Ãµµ ±³¼ö´ÔÀÇ °ÀÇ Àß µé¾ú½À´Ï´Ù. Áö¹æ °ËÁø¼¾ÅÍ¿¡¼ ÀÏÇÏ´Â ¼Òȱ⳻°ú ÀÇ»çÀÔ´Ï´Ù. Àú´Â ¸ÅÀÏ ¾Æħ Ãâ±ÙÇϸé Ä¿ÇÇ ÇÑÀÜ ¸¶½Ã¸é¼ ±³¼ö´ÔÀÇ ¸ÞÀÏÀ» º¸´Â ½Ã°£ÀÌ ÇÏ·ç Áß °¡Àå Áñ°Å¿î ½Ã°£ÀÎ°Í °°½À´Ï´Ù.
´Ù¸§¾Æ´Ï¶ó ±³¼ö´Ô²²¼ Åõ°íÇϼ̴ø ³í¹®ÀÇ ´ë·«ÀûÀÎ ¿äÁö´Â Àß ¾Ë°Ú½À´Ï´Ù¸¸, 'º´¸®°ú¿¡¼ ¾ó¸¶³ª cancer cellÀ» Àß Ã£¾Æ¼ ºÁÁִ°¡?' µµ ÇϳªÀÇ ¹®Á¦ÀÎ°Í °°½À´Ï´Ù. ÀÏÀü¿¡(Æç·Î¿ì ¼ö·Ã¹ÞÀ»¶§) LMC(local medical center)¿¡¼ ¾Ï Áø´ÜÀ» ¹Þ°í ÀÇ·ÚµÈ È¯ÀÚ°¡ ÀÖ¾ú´Âµ¥, Á¦°¡ Á¤È®ÇÑ º´¼Ò¿¡ (ºñ±³Àû Á¤È®ÇÏ°Ô) target biopsy ½ÃÇàÇß´Ù°í »ý°¢Çߴµ¥ °á°ú´Â negative·Î ³ª¿Ô½À´Ï´Ù. ÀÌ»óÇؼ º´¸®°ú¿¡ ã¾Æ°¡º¸°í, Á˼ÛÇÏÁö¸¸ ½½¶óÀÌµå ¸®ºä¸¦ ÇÒ ¼ö Àְڳİí (°¨È÷) ºÎŹµå·È´ø °á°ú.. ½½¶óÀ̵åÀÇ ÇÑÂÊ ³¡ºÎºÐ¿¡¼ Signet ring cellÀÌ °Ü¿ì È®ÀÎµÈ °æ¿ì°¡ ÀÖ¾ú½À´Ï´Ù.
¾Æ¹«Æ°, ÀúÈñ°¡ Çß´ø °Ë»çµéÀÌ ¸ðµÎ Á¤È®Çß°í, º´¸®°ú°¡ Àß ¸øÇߴٴ°ÍÀº ¾Æ´ÏÁö¸¸.. º´¸®°ú¿¡¼µµ ¾Ï ¼¼Æ÷¸¦ ³õÄ¥ ¼ö Àִٴ°͵µ »ý°¢ÇÏ°í ÀǽÉÇغ¸¾Æ¾ß ÇÒ°Í °°½À´Ï´Ù. (ÀÌ·± ³»¿ëÀ» ÀûÀ¸¸é ÇÐȸ¿¡¼ reject´çÇÒÁöµµ ¸ð¸£°ÚÁÒ? ¼Òȱ⳻°ú¿Í º´¸®°ú»çÀÌ¿¡ ºÐ¶õÀÌ ÀϾ ¼öµµ ÀÖ´Â ¹®Á¦¶ó....)
´õ¿î ¿©¸§ÀÔ´Ï´Ù. °Ç°ÇϽʽÿÀ^^
[2016-8-5. ÀÌÁØÇà ´äº¯]
°¨»çÇÕ´Ï´Ù. ¿ÇÀº ¸»¾¸ÀÔ´Ï´Ù. º´¸® Àǻ絵 ¿Ïº®ÇÏÁö´Â ¾Ê½À´Ï´Ù.
³»½Ã°æ Àǻ絵 Àú¼ö°¡¿Í °ú·Î¿¡ ½Ã´Þ¸®´Â °Íó·³ º´¸®°ú Àǻ絵 Àú¼ö°¡¿Í °ú·Î¿¡ ½Ã´Þ¸³´Ï´Ù. ÀÌÁ¦ ¿ì¸® ÀÇ·á´Â Á» ´õ Ç°À§ÀÖ°Ô ¹Ù²î¾î¾ß ÇÕ´Ï´Ù. ½Î±¸·Á´Â ÀÌÁ¦ ±×¸¸!
Fellow ½ÃÀý º´¸®°ú¸¦ ã¾Æ°¡ "Á˼ÛÇÏÁö¸¸ ½½¶óÀÌµå ¸®ºä¸¦ ÇÒ ¼ö ÀÖ°Ú³Ä"°í ºÎŹÇÏ¿© ±¸¼®¿¡¼ signet ring cell carcinoma¸¦ ã¾Æ³»¼Ì´Ù´Â °æÇè´ãÀº Âü Èå¹µÇÑ ¿¡ÇǼҵåÀÔ´Ï´Ù. ´ç¿¬È÷ ±×·¡¾ß ÇÕ´Ï´Ù. CT °Ë»ç °á°ú¿¡ Á¶±ÝÀÌ¶óµµ Àǹ®ÀÌ ÀÖÀ¸¸é ¿µ»óÀÇÇаú Æǵ¶½ÇÀ» ã¾Æ°¡ ÇÔ²² CT¸¦ º¸¸é¼ Åä·ÐÇØ¾ß ÇÕ´Ï´Ù. º´¸® °Ë»ç °á°ú¿¡ Á¶±ÝÀÌ¶óµµ Àǹ®ÀÌ ÀÖÀ¸¸é º´¸® Æǵ¶½ÇÀ» ã¾Æ°¡ ÇÔ²² slide¸¦ º¸¸é¼ Åä·ÐÇØ¾ß ÇÕ´Ï´Ù. ³»½Ã°æ °Ë»ç °á°ú¿¡ Á¶±ÝÀÌ¶óµµ Àǹ®ÀÌ ÀÖÀ¸¸é ³»½Ã°æ½ÇÀ» ã¾Æ°¡ ÇÔ²² »çÁøÀ» º¸¸é¼ Åä·ÐÇØ¾ß ÇÕ´Ï´Ù. ±×·±µ¥ ±×°Ô ¾î·Æ½À´Ï´Ù. Àúµµ °ÅÀÇ ¸øÇÕ´Ï´Ù. µµ¹«Áö ½Ã°£À» ³¾ ¼ö ¾ø½À´Ï´Ù. ÀÓ»ó Àǻ簡 ³Ê¹« ¹Ù»Û °ÍÀº ¹°·ÐÀÌ°í, ¿µ»óÀÇÇаú, º´¸®°ú, ³»½Ã°æ ÀÇ»ç ¸ðµÎ ³Ê¹« ¹Ù»Þ´Ï´Ù. ´Ùµé ¼µÎ¸¦ »ÓÀÌÁö Â÷ºÐÈ÷ »ý°¢ÇÏ°í Åä·ÐÇϸç ȯÀÚ¸¦ Áø·áÇÒ ¼ö ¾ø½À´Ï´Ù. ¹°·Ð ÁÖ¹üÀº 'Àú¼ö°¡ ȯ°æ'ÀÔ´Ï´Ù. ¿ÀÁ×ÇßÀ¸¸é ÀúÀÇ ¸ðÅä°¡ 'ºü¸¥ ³»½Ã°æº¸´Ù ¹Ù¸¥ ³»½Ã°æ!'ÀÌ°Ú½À´Ï±î? ¿ÀÁ×ÇßÀ¸¸é Á¦°¡ ¿î¿µÇÏ´Â ¿¬±¸¼ÒÀÇ À̸§ÀÌ 'ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò'ÀÌ°Ú½À´Ï±î?
¿¾ÇÇÑ È¯°æ¿¡¼µµ ȯÀÚ¸¦ À§ÇÏ¿© ¿½ÉÈ÷ ÀÏÇÏ´Â ¿©·¯ºÐÀ» Á¸°æÇÕ´Ï´Ù. '³»½Ã°æ Àç°Ë'À» ó¹æÇϱ⿡ ¾Õ¼ º´¸®°ú¿¡ ã¾Æ°¡ °¨È÷ ÀçÆǵ¶À» ºÎŹÇϼ̴ø ¼±»ý´ÔÀ» Á¸°æÇÕ´Ï´Ù. °¨È÷ ÀçÆǵ¶À» ºÎŹÇÒ °ÍÀÌ ¾Æ´Ï¶ó, ´Ã ÀÚ¿¬½º·´°Ô ÀçÆǵ¶À» ºÎŹÇÒ ¼ö Àִ ȯ°æÀ» ±â´ëÇÕ´Ï´Ù. Àúµµ ³ª¸§´ë·Î ³ë·ÂÇÏ°Ú½À´Ï´Ù.
* Âü°í: EndoTODAY ¸»Æ®¸²ÇÁÁ¾
3. Circumferential heterotopic gastric mucosa
»óºÎ½ÄµµÀÇ À̼Ҽº À§Á¡¸· (inlet patch, heterotopic gastric mucosa)Àº º¸Åë µÕ±Ù ¸ð¾çÀÔ´Ï´Ù. ±×·¯³ª semi-circular ȤÀº circularÇÑ °æ¿ì°¡ ÀÖ½À´Ï´Ù. Á¶Á÷°Ë»ç´Â acanthotic squamous epithelium and gastric mucosal showing chronic gastritis, active with intestinal metaplasia·Î ³ª¿Ô½À´Ï´Ù. ÃßÀû °üÂû¸¸ ½ÃÇàÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
* Âü°í: EndoTODAY À̼Ҽº À§Á¡¸·
4. Esophageal stricture due to reflux esophagitis
¿ª·ù¼º ½Äµµ¿°Àº ÁÖ·Î on demand PPI·Î Ä¡·áÇÏÁö¸¸, ¸Å¿ì ½ÉÇÑ °æ¿ì¿Í stricture°¡ ¹ß»ýÇϱ⠽ÃÀÛÇÑ °æ¿ì¿¡´Â Áõ»ó°ú ¹«°üÇÏ°Ô daily PPI¸¦ ¾²µµ·Ï ±ÇÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ¾Æ·¡´Â ÀÌ È¯ÀÚÀÇ °ú°Å ³»½Ã°æÀÔ´Ï´Ù.
Á¶Á÷°Ë»ç´Â P/D adencarcinoma¿´°í peritoneal seeding, transverse colon and pancreas invasionÀÌ ÀÖ¾ú½À´Ï´Ù.
1) SMC Endoscopy Unit »ï¼º¼¿ïº´¿ø ³»½Ã°æ½Ç
2) SMC Monday GI conference »ï¼º¼¿ïº´¿ø ÀÏ¿ø³»½Ã°æ±³½Ç ¿ù¿äÁ¡½É¼ÒȱâÁý´ãȸ
3) SMC Endoscopy conference »ï¼º¼¿ïº´¿ø ÀÏ¿ø³»½Ã°æ±³½Ç ¸ñ¿äÁ¡½É³»½Ã°æÁý´ãȸ
© EndoTODAY Endoscopy Learning Center. Jun Haeng Lee. ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà.